Dr Jennifer McQuade
Medical Oncologist · Precision Oncology Specialist · Former Associate Professor
Formerly MD Anderson Cancer Center · Houston, Texas
MD, MS, MA, FASCO
The science
The same data oncologists already collect, analysed to identify what's actually driving the cancer.
Astron sits between the molecular lab and the consultant oncologist. We turn raw multi-omic data into something a clinician can act on.
Inputs
Molecular profile
Multi-omic data from your tumour sample.
→
Astron platform
Interpretation engine
Integrates the real biological signal, not a proxy, to model whether the pathway is driving the tumour.
→
Output
Per-patient roadmap
A ranked, evidence-graded list of research-described treatment options, structured to support the clinician's prescribing decision.
Astron interpretation engine
Our platform integrates the real biological signal, not a proxy, to model whether a pathway is actually driving the tumour. We score every drug-gene pair against the patient's individual molecular context, not against a generic tumour-type playbook.
170k+
Drug-gene interactions reviewed
~20k
Genes analysed in every molecular profile
1
Clear, actionable report for your case
How we rank interventions
The most evidenced option, for this patient.
We don't just surface treatments, we weigh each one across the factors that matter for this specific patient, from pathway dependency to clinical-trial maturity, to identify the option with the strongest evidence behind it. Every rank is fully decomposed, so theconsultant oncologist can see exactly what drives it.
Pathway dependency92.00
Drug-target evidence86.00
Tumour-type relevance78.00
Clinical-trial maturity72.00
Patient-context fit91.00
Sample report
Explore a full Astron molecular report.
Explore the clinician synthesis, treatment roadmap, molecular findings and detailed appendices. This specimen uses a fictional patient and synthetic data for demonstration only. It is not for clinical use.
Who reviews your case
Meet your molecular tumour board.
Every Astron second opinion is reviewed and signed off by a molecular tumour board of world-leading oncologists and researchers, drawn from institutions including MD Anderson Cancer Center, the University of Birmingham, The London Clinic and St Bartholomew's Hospital.
Professor Shivan Sivakumar
Professor of Translational Oncology · Consultant Medical Oncologist
University of Birmingham · University Hospitals Birmingham
MBBS, BMedSci, PhD, FRCP
Dr Abinav Baweja
Hematologist & Medical Oncologist
Stanford University Medical Partners · Santa Clara Valley Healthcare
MD, Board-Certified in Hematology & Medical Oncology
Dr Samir Agrawal
Consultant Haemato-Oncologist · Senior Lecturer in Haemato-oncology
St Bartholomew's Hospital, Barts Health NHS Trust · Queen Mary University of London
MB ChB, FRCP, FRCPath, PhD
Dr Roba Alhasan
Hematologist & Medical Oncologist · Former Clinical Assistant Professor
Formerly University of Chicago Medicine · UCLA-affiliated Kern Medical
MD, Board-Certified in Medical Oncology
Dr Andy Gaya
Consultant Clinical Oncologist
The London Clinic · Cromwell Hospital, London
MBBS, MD, MRCP, FRCR
Dr Tim Crook
Consultant Medical Oncologist
The London Clinic · Cromwell Hospital, London
MBBS, PhD, FRCP
Dr Miguel Albino
Medical Oncologist & Hematologist
Texas Oncology · Austin, Texas
MD, Board-Certified in Medical Oncology
Begin
Bring this depth of analysis to your case.
One package. One fixed price. From molecular analysis to a second opinion signed off by world-leading oncologists, ready to take to your own doctor.